ʻEiwa mau mahina ma hope o kona hoʻokomo ʻana i ka US, ʻo Eisai a me Biogen's Alzheimer's drug Leqembi halawai ana ke kū'ē nui i kona hoʻopaʻa ʻia ʻana, ʻo ka hapa nui ma muli o ka kānalua i waena o kekahi mau kauka e pili ana i ka pono o ka mālama ʻana i kēia maʻi lolo degenerative.
ʻOiai ʻo ia ka lāʻau lapaʻau mua i hōʻike ʻia e hoʻolōʻihi i ka piʻi ʻana o ka maʻi o Alzheimer, ʻo nā kānalua paʻa i waena o nā mea mālama olakino e pili ana i ka waiwai o ka mālama ʻana i ke ʻano ke hōʻike nei he mea keakea nui.
Ua manaʻo mua ka poʻe loea o Alzheimer i nā luʻi e pili ana i ka protocol koi a Leqembi, e komo pū ana i nā hoʻokolohua diagnostic hou, nā infusions ʻelua mahina, a me ka nānā ʻana i ka lolo maʻamau e nānā i nā hopena ʻaoʻao koʻikoʻi. ʻOiaʻiʻo, ua kōkua kēia mau koi i ka lawe lohi ʻana o ka lāʻau mai kona ʻae ʻia e ka US Food and Drug Administration, e like me ka ʻike ʻia e nā kūkākūkā me 20 neurologists a me geriatricians ma nā wahi like ʻole o US.
Wahi a Reuters, ʻehiku mau kauka i hōʻike i ko lākou kānalua e kuhikuhi iā Leqembi, e hōʻike ana i nā kānalua e pili ana i ka pono o ka lāʻau lapaʻau, kona kumukūʻai, a me nā pilikia pili. Eia kekahi, ua hōʻike ʻia kahi hui o ʻeono mau loea alakaʻi ma ke kula ʻo "therapeutic nihilism" - ka manaʻo he ʻano hiki ʻole ke hoʻokō ʻia ʻo Alzheimer - he hopena koʻikoʻi ma mua o ka mea i manaʻo ʻia i ka hoʻopaʻa ʻana i ka hoihoi ma waena o nā kauka mālama mua, geriatricians, a me nā neurologists. Hoʻopilikia kēia kānalua i ko lākou makemake e kuhikuhi i nā mea maʻi i nā loea hoʻomanaʻo no ka mālama ʻana me Leqembi.
Wahi a kekahi poʻe loea, ʻo ka makemake ʻole i waena o kekahi mau kauka ke kumu mai ka lōʻihi o ka kānalua i uhi i ka pono o ka huli ʻana i ka protein beta amyloid Alzheimer e hoʻolōʻihi i ka piʻi ʻana o ka maʻi. Ma mua o nā hopena hoʻoikaika o ka hoʻokolokolo ʻo Leqembi, ua manaʻo nui ka poʻe i ka lāʻau lapaʻau i kēia kuhikuhi noiʻi ʻaʻole hua.
Ua hāpai ʻia nā manaʻo hopohopo e nā mea lapaʻau ʻē aʻe e pili ana i nā hopena ʻaoʻao o Leqembi, e like me ka pehu ʻana o ka lolo a me ke kahe ʻana o ke koko, me ka hoʻohui ʻana i nā kumukūʻai e pili ana me ka $26,500 makahiki kumu kūʻai, MRI pinepine, a me nā infusions ʻelua mahina.
ʻO Leqembi ka lāʻau amyloid-targeting mua loa i loaʻa ka ʻae piha FDA ma hope o ka hōʻike ʻana i kahi 27% lohi i ka emi ʻana o ka cognitive ma waena o nā maʻi maʻi Alzheimer mua i ka wā o nā hoʻokolohua lapaʻau. ʻOiai ʻo ka pahuhopu mua e mālama i 10,000 ʻAmelika i ka hopena o Malaki, he mau kaukani wale nō i hoʻomaka i ka mālama ʻana ma ka hopena o Ianuali, e like me ka hōʻike ʻana e Eisai, ʻaʻole i hōʻole ka mea haʻiʻōlelo e hāʻawi i nā helu hou.
ʻO ka lawe ʻana i nā lāʻau lapaʻau hou, ʻo ia hoʻi nā mea ʻaʻole i koi i nā loli koʻikoʻi i ka hoʻomaʻamaʻa olakino, ua lohi loa. Ua hōʻike ʻia ka noiʻi hiki ke lawe i ka awelika o 17 mau makahiki no ka noiʻi lapaʻau e lilo i hana maʻamau. Hoʻopilikia ka Alzheimer ma luna o 6 miliona ʻAmelika, akā ʻoi aku ka liʻiliʻi ma mua o ka hapalua o nā neurologist US e ʻōlelo nei iā Leqembi i kā lākou poʻe maʻi, e like me ka hōʻike o Ianuali ma ke ola. ʻikeʻike mea noiʻi mākeke ʻo Spherix Global Insights.
i kakauia ma Alius Noreika
